![]() This involves leveraging not one or many, but the proper digital technologies and capabilities to change the way companies discover, create, make and sell new products,” says Sachin Misra, Principal and Global Pharmaceuticals Leader at Kalypso. “Our experience in deploying next-generation emerging and disruptive technologies helps us focus on the digital transformation of every aspect of the value chain, from the product to the plant to the end user. Its in-depth industry knowledge, hands-on experience and established relationships with leading solution providers in the digital transformation space help it work on applicable technology solutions that solve complex business challenges for life sciences companies. Whether optimizing the product portfolio mix, accelerating speed to market, enabling digital tech transfer, improving operations performance, maximizing asset uptime and availability, optimizing supply chains, defining sustainability and energy management solutions, or managing organizational change, Kalypso assists life sciences organizations in maximizing their productivity and efficiency while decreasing time to revenue and increasing margins. To ultimately deliver safe, efficacious and lifesaving products to patients as quickly as possible, they also need a scalable digital strategy to improve their operational efficiencies while maintaining regulatory compliance, and ensuring data integrity.Īs a digital leader in end-to-end advisory, implementation and support services, Kalypso has been perfecting digital transformation strategy and delivery for decades. It also impedes efficient tech transfer, scale-up, supply chain resilience and distributed global manufacturing.ĭrug products marketed and manufactured across global jurisdictions are now requiring multiple manufacturing modalities, flexible manufacturing processes, multifaceted talent and composite organizational structures. The various industry segments such as traditional Pharmaceuticals, Biologics, ATMP (Advanced Therapy Medicinal Products) and CDMO (Contract Development and Manufacturing Organization) add further complexity and nuance to processes that IT (Information Technology) and OT (Operational Technology) systems have to address while avoiding technical debt. Visibility of structured product, process, supply chain, risk and quality data across the value chain is a challenge due to the inherent complexity and manufacturing modalities of the industry. Sachin Misra, Principal Extended value chains and networks in the life sciences industry are becoming more global, with an increasing number of stakeholders and trading partners. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |